Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
-
A4356 Varespladib (LY315920)Target: PhospholipasesSummary: HnsPLA inhibitor,potent and selective
-
B1169 GSK 2830371Summary: Orally active, allosteric inhibitor of Wip1 phosphatase
-
A8403 CP-91149Target: Glycogen PhosphorylasesSummary: Selective inhibitor of glycogen phosphorylase
-
B6067 N-(p-amylcinnamoyl) Anthranilic AcidSummary: phospholipase A2 (PLA2) inhibitor and TRP channel blocker
-
C3364 7-hydroxycoumarinyl ArachidonateSummary: substrate for cPLA2
-
C5081 Bromoenol lactoneSummary: Inhibitor of myocardial cytosolic calcium-independent phospholipase A2 (iPLA2)
-
C3919 VU0359595Summary: PLD1 inhibitor
-
C3779 Arachidonic Acid LeelamideSummary: phospholipase A2 inhibitor
-
C3792 Oleyloxyethyl PhosphorylcholineSummary: PLA2 inhibitor
-
C4385 HalopemideSummary: phospholipase D (PLD) inhibitor